Alois Alzheimer described the etiology of Alzheimer’s disease over a century ago. Its prevalence has increased dramatically in the last few decades, resulting in serious increases in health care costs. Its multifactorial etiology includes extracellular amyloid beta accumulation, formation of intracellular neurofibrillary tangles, oxidative stress, gene mutations, neuroinflammation, metal dyshomeostasis, and apoptosis. Therapeutic approaches have included bioactive compounds, nanoparticles, drug delivery systems, and viral vector therapeutics, but have all yielded limited success.
Despite the difficulty of drug delivery to the brain, there are some nanoparticulate platforms demonstrating promise in treating neurodegenerative disorders in general and Alzheimer’s disease in particular. Manifold theranostic maneuvers include antioxidants, natural bioactive compounds, gene therapy, and nanotechnological approaches. These bioactive compounds, therapeutic peptides, nucleic acids, and drugs are typically loaded in various nanoparticles to overcome the enhanced permeation and retention (EPR) effect and avoid reticulo-endothelial system (RES) uptake.
Their success in clinical trials is limited at present. This has caused robust debate among researchers about whether these nanoparticles are a milestone in the treatment of Alzheimer’s or a mirage. This book shines a light on recent inventions in the various theranostic avenues for both diagnosis and treatment of Alzheimer’s patients. It also discusses the pros and cons of the probable mechanistic role of nanoparticles in crossing the blood-brain barrier and improving disease symptoms. Finally, it highlights the merits of existing manoeuvers and suggests perspectives to aid in future developments.
- Examines various theranostic applications for the diagnosis and treatment of Alzheimer’s disease
- Features a comprehensive overview of nanoparticle therapeutics in the area and the use of antioxidants
- Assesses the common challenges and lessons learned from blood-brain barrier challenges, viral vector approaches, and mitochondria-targeted therapeutics
Neuroscientists, biomedical researchers and graduate students, medical students. Materials science and biomaterials/biomedical engineering researchers/students, nutrition professionals
Chapter 1: Introduction: Alzheimer’s Disease Pathology and Therapeutics
Chapter 1 focuses on an overview of Alzheimer’s pathology and current therapeutic strategies. It also highlights the shortcomings of existing therapeutic strategies.
Chapter 2: Early Diagnosis of Alzheimer’s Disease: Pros and Cons
The multitude of theranostic tools employed to diagnose the disease will be highlighted in this chapter.
Chapter 3: Antioxidants in Alzheimer’s Therapy
Chapter 3 highlights the wide range of antioxidants used in the treatment of Alzheimer’s and their associated bioavailability issues, where applicable.
Chapter 4: Natural Compounds in the Treatment of Alzheimer’s Disease
Although various natural compounds have been employed to treat Alzheimer’s, their success is limited by a few shortcomings. This chapter focuses on the pros and cons of compounds currently in use.
Chapter 5: Blood Brain Barrier
A wide range of strategies have been employed to overcome blood brain barrier challenges. A review of more recent findings will be highlighted in this chapter.
Chapter 6: Gene Therapy: The Cornerstone in the Development of Alzheimer’s Disease Therapeutics
More recently, researchers have employed gene therapy strategies to overcome neurodegeneration. This chapter highlights these strategies.
Chapter 7: Viral vector therapeutics against Alzheimer’s Disease
Extensively used viral vector therapeutics for treating Alzheimer’s will be highlighted in this chapter.
Chapter 8: Mitochondria-Targeted Nanoparticles: A Milestone or a Mirage in the Treatment of Alzheimer’s Disease
Mitochondria targeting has been of utmost important for nanotechnology researchers due to its potential to combat several diseases. They are highlighted as are shortcomings and future perspectives.
Chapter 9: Nanoparticles: The Double-Edged Swords
Despite the significant therapeutic efficacy of antioxidants, short systemic circulation impedes their success. This chapter focuses on nanoformulations that have been discovered to overcome these issues.
Chapter 10: Alzheimer Therapeutics: Pros and Cons
Although many therapeutics strategies have been employed since the discovery of the disease, there remain no appropriate therapeutics to overcome it. This chapter highlights current limitations and future perspectives
- No. of pages:
- © Academic Press 2019
- 1st February 2019
- Academic Press
- Paperback ISBN:
M. Obulesu is a Scientist in ATG Laboratories, Pune, India. He has 18 years of research and teaching experience. His research areas are multifarious which include food science, pathology of Neurodegenerative diseases such as Alzheimer’s disease and designing polymer based Biomaterials (Design of hydrogels etc.). He did Alzheimer’s disease research and developed an aluminium induced neurotoxicity rabbit model. His present research focuses on development of redox-active injectable hydrogels of polyion complex. His research area also includes development of metal chelators to overcome metal induced toxicity. He is the first and corresponding author for majority of his articles. He secured a certificate from Stanford University for the Scientific Writing course. He is on editorial board of a few pathology journals such as Journal of Medical Laboratory and Diagnosis, Journal of Medical and Surgical Pathology, Annals of Retrovirals and Antiretrovirals, Kenkyu Journal of Medical Science and Clinical Research, SciFed Oncology and Cancer Research Journal, Journal of Cancer and Cure. He is also on editorial board of nanotechnology journals such as SciFed Nanotech Research Letters, SciFed Drug Delivery Research, Current Updates in Nanotechnology and Journal of Nanotechnology and Materials Science.
Scientist, ATG Laboratories, Pune, India, Certified by Stanford University for Scientific Writing